Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

Breast Cancer Research and Treatment
Lisa RydénMårten Fernö

Abstract

Triple-negative breast cancer (TNB) has poor prognosis and moreover patients with TNB do not benefit from established targeted drugs with endocrine therapy or trastuzumab. The aim of the study was to analyze the prevalence of candidate biomarkers in tumors from patients with TNB. Tissue microarrays were prepared from primary tumors from premenopausal breast cancer patients (500/564) randomized to adjuvant tamoxifen or no adjuvant treatment. Immunohistochemical (IHC) staining included ER, PR, HER2, epidermal receptor growth factor (EGFR), vascular endothelial growth factor A (VEGF-A), and vascular endothelial growth factor receptor 2 (VEGFR2). EGFR and HER2 gene copy number was defined by fluorescence in situ hybridization (FISH). All patients were included in the descriptive analysis, but only untreated patients in the survival analysis. TNB was diagnosed in 96 patients and correlated significantly to low age, Nottingham histological grade (NHG) III, high Ki67-index, T2 tumors, node negativity, EGFR positivity, increased EGFR gene copy number and high VEGFR2 expression. TNB was an independent prognostic factor for decreased 5-year breast cancer specific survival (BCSS) (HR 2.0 (95% CI 1.1-3.6), P = 0.01), but not for 10-year BC...Continue Reading

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Jan 22, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lisa RydénUNKNOWN South-East Swedish Breast Cancer Group
Dec 13, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Chad A LivasyCharles M Perou
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Dec 6, 2006·Cancer·Emad A RakhaIan O Ellis
Dec 26, 2006·Molecular Cancer Research : MCR·Marjut PuputtiNina N Nupponen
Feb 24, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F R HirschP A Bunn
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Sep 22, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Enrique LermaAgustí Barnadas
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinKathy D Miller
Mar 28, 2008·Expert Review of Molecular Diagnostics·Christian Ensinger, William Sterlacci
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschDavid R Gandara
Sep 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicola PersoneniSabine Tejpar
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bryan P SchneiderLisa A Carey
Jul 28, 2009·Maturitas·Sumanta Kumar Pal, Joanne Mortimer
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa A CareyEric P Winer

❮ Previous
Next ❯

Citations

Jul 16, 2010·International Journal of Clinical Oncology·Yutaka Yamamoto, Hirotaka Iwase
Jun 25, 2010·Breast Cancer Research and Treatment·Jung Ah LeeUNKNOWN Korean Breast Cancer Society
Sep 7, 2011·Breast Cancer Research and Treatment·Brant PohorelicA Magliocco
Oct 12, 2011·Current Opinion in Oncology·Sheeba IrshadAndrew Tutt
Jun 10, 2011·BMC Cancer·Angela P PressonSteve Horvath
Sep 24, 2010·Molecular Endocrinology·Daniel J Toft, Vincent L Cryns
Jul 13, 2011·Pathology Research International·Ewe Seng Ch'ngSharifah Emilia Tuan Sharif
Jan 1, 2014·Archives of Pathology & Laboratory Medicine·Jennifer LeidyDina Kandil
Jun 13, 2013·Biochimica Et Biophysica Acta·Caroline E Nunes-XavierRafael Pulido
Nov 5, 2013·Biochimica Et Biophysica Acta·Weiqiang ZhouShanchun Guo
Oct 27, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Saori FujiwaraHirotaka Iwase
Sep 6, 2011·Virchows Archiv : an International Journal of Pathology·Juliana Silva ZanettiAlfredo Ribeiro-Silva
Apr 13, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Eloisa Jantus-LewintreCarlos Camps
May 14, 2011·Molecular Aspects of Medicine·Sònia TuguesLena Claesson-Welsh
Apr 11, 2014·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Fatemeh BahreiniParvin Mehdipour
May 15, 2012·International Journal of Cancer. Journal International Du Cancer·Michael J DuffyJohn Crown
Oct 19, 2011·Journal of Oncology·Elham Fakhrejahani, Masakazu Toi
Oct 14, 2014·Expert Opinion on Therapeutic Targets·Anselmo PapaFederica Tomao
Dec 22, 2014·Hematology/oncology and Stem Cell Therapy·H A AlagizyM M Swiha
Sep 15, 2014·Cancer Treatment Reviews·Arnoud J TempletonAlberto Ocaña
Nov 8, 2016·Expert Reviews in Molecular Medicine·Cornelia BraicuIoana Berindan-Neagoe
Feb 27, 2016·Oncotarget·Milos Z MilosavljevicMiodrag L Lukic
Oct 11, 2019·Journal of breast cancer·Maryam NakhjavaniAmanda R Townsend

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.